Veselibu Clinic
| ギリシャ | トルコ | オーストリア | |
| 神経芽細胞腫の複雑治療 | - | から $28,000 | から $180,000 |
Bookimedは神経芽腫治療価格に追加料金を加算しません。料金はクリニックの公式価格表から来ています。国に到着時にクリニックで治療代を直接お支払いいただきます。
Bookimedはお客様の安全に取り組んでいます。神経芽腫治療で高い国際基準を維持し、世界中の国際患者サービスに必要なライセンスを有する医療機関とのみ協力しています。
Bookimedは無料専門サポートを提供します。専属医療コーディネーターが治療前、治療中、治療後にサポートし、あらゆる問題を解決します。神経芽腫治療の旅路でお一人になることはありません。
Pediatric neuroblastoma is primarily treated in specialized oncology units in Athens and Thessaloniki. The Marianna Vardinoyannis ELPIDA Children's Oncology Unit is the leading center. It treats 30% of Greek pediatric cancer cases and offers autologous stem cell rescues in dedicated units.
Bookimed Expert Insight: While local centers like Veselibu Clinic in Thessaloniki meet international standards for rehabilitation, acute neuroblastoma care is concentrated in large university hubs. Our data shows that complex cases naturally flow to Athens. Most top-tier public facilities there serve over 2,000 patients yearly. This high volume ensures teams stay proficient in rare embryonal tumor protocols.
Patient Consensus: Patients note it is vital to keep all care in one specialized center. They emphasize asking about the team's specific case volume for rare tumors like neuroblastoma. Most families recommend getting a second opinion on pathology and staging before starting treatment.
Greek hospitals strictly follow internationally recognized neuroblastoma protocols established by the International Society of Pediatric Oncology Europe Neuroblastoma Group (SIOPEN). Pediatric oncology units utilize the International Neuroblastoma Risk Group Staging System (INRGSS) to standardize diagnosis. Treatment pathways align with pan-European clinical research frameworks for consistency.
Bookimed Expert Insight: Greek pediatric oncology centers like those in Thessaloniki serve approximately 2,000 patients annually. While smaller than some European hubs, their government-certified facilities for international patients guarantee compliance with EU-wide standards. This ensures high-risk protocols like the MONALISA project trials are accessible without traveling to Western Europe.
Patient Consensus: Families emphasize that protocol consistency is more important than hospital reputation alone. They recommend confirming if local teams coordinate with international groups for high-risk case management.
Greek centers follow SIOPEN protocols developed by the Society of Pediatric Oncology Europe Neuroblastoma. Plans are strictly risk-adapted based on tumor biology and age. High-risk cases use the Rapid COJEC chemotherapy regimen. This intensive cycle delivers eight treatments every ten days to target metastases aggressively.
Bookimed Expert Insight: Greek pediatric oncology centers coordinate multi-phase care across specialized departments. For example, Thessaloniki facilities like Veselibu Clinic manage high patient volumes and maintain infrastructure for complex recovery. While some centers focus on the primary surgery, high-risk protocols require a facility with integrated pediatric ICU and stem cell capabilities.
Patient Consensus: Patients note that tumor biology markers often change the treatment plan more than tumor location does. They emphasize that surgery is usually safer after chemotherapy cycles have effectively shrunk the initial mass.
Anti-GD2 immunotherapy is available in Greece at specialized pediatric oncology centers for high-risk neuroblastoma. These monoclonal antibodies require intensive monitoring for neuropathic pain. Access usually depends on protocol eligibility. Tertiary centers in Athens and Thessaloniki coordinate these complex treatments.
Bookimed Expert Insight: Greek patients often find that smaller regional clinics lack the infrastructure for anti-GD2 monitoring. Veselibu Clinic in Thessaloniki maintains government certification for international standards. However, neuroblastoma cases frequently require transfer to larger academic hospitals. Confirm if your center has a dedicated pain-control protocol before starting.
Patient Consensus: Patients emphasize that anti-GD2 is a physically demanding treatment involving fever and pain. It is vital to ask your oncologist early if this therapy is included in your child's specific risk-group plan.
Full autologous stem-cell transplants are performed in Greece. These procedures follow European Union standards for oncology. Facilities like Agia Sofia Children hospital provide specialized pediatric care. Treatments often combine high-dose chemotherapy with stem-cell rescue. Greek centers must adhere to strict regulatory protocols.
Bookimed Expert Insight: While Greece maintains specialized centers like Veselibu Clinic, which serves 2,000 patients annually, pediatric neuroblastoma cases require highly specific equipment. Success often depends on on-site stem-cell cryogenic storage and rapid fever response teams. Patients should verify if a facility handles the entire sequence from induction to consolidation.
Patient Consensus: Parents emphasize that center selection matters more than the transplant technique itself. They note it is vital to check if the hospital team handles pediatric complications daily.
Relapsed or refractory neuroblastoma is treated with multimodal strategies to induce a second remission. Primary options include re-induction chemotherapy, targeted radiation like iodine-131-MIBG therapy, and immunotherapy. Greece offers advanced pediatric oncology services, including specialized CAR NK cell therapy and complex multidisciplinary care at accredited facilities.
Bookimed Expert Insight: While many families seek centers in Turkey or Spain due to high volumes, Greece provides a vital gateway for advanced cellular therapies like CAR NK cell therapy. Facilities like Veselibu Clinic in Thessaloniki manage 2,000+ patients annually. This indicates strong local capacity for complex pediatric supportive care during intensive salvage regimens.
Patient Consensus: Patients note it is important to focus on trial eligibility after a relapse. Families emphasize getting a molecular biopsy to find the next practical treatment option.